ערך בספרים למניה: Burning Rock (BNR)

Burning Rock Biotech (BNR) is scaling the implementation of NGS tests through B2B contracts, as reflected in the GURU.Markets terminal, where the book value indicator shows a current metric of 6.95. A leading position in Chinese diagnostics and government support strengthen the base, while a strong staff of biologists ensures stable potential, minimizing risks as the business develops its fundamental value.

The integration of robotic sequencers and AI into Burning Rock Biotech (BNR) oncology diagnostics is reflected in the book value per share chart, demonstrating the capitalization of technological capabilities. This indicator is calculated as the ratio of total net assets to the number of shares, allowing investors to assess the real value of their ownership stake and the resilience of the company's resources to cover its liabilities.